Clinical Trials
35 trialsPI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI)
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
National Cancer Institute (NCI)
Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
National Institutes of Health Clinical Center (CC)
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer
National Cancer Institute (NCI)
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
National Cancer Institute (NCI)
Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
National Cancer Institute (NCI)
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
National Cancer Institute (NCI)
Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
National Institutes of Health Clinical Center (CC)
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
National Cancer Institute (NCI)
Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Women With Resected Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer
National Cancer Institute (NCI)
Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)